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Carbapenems are the primary choice of treatment for severe Pseudomonas aeruginosa infection. However, the emergence of
carbapenem resistance due to the production of metallo-β-lactamases (MBLs) is of global concern. In this study, 90 imipenem-
(IPM- or IP-) resistant P. aeruginosa (IRPA) isolates, including 32 previously tested positive and genotyped for MBL genes by PCR,
were subjected to double-disk synergy test (DDST), combined disk test (CDT), and imipenem/imipenem-inhibitor (IP/IPI) E-test
to evaluate their MBLs detection capability. All three methods were shown to have a sensitivity of 100%. However, DDST was
the most specific of the three (96.6%), followed by IP/IPI E-test interpreted based on the single criteria of IP/IPI ≥ 8 as positive
(62.1%), and CDT was the least specific (43.1%). Based on the data from this evaluation, we propose that only IRPA with IP MIC
> 16 μg/mL and IP/IPI ≥ 8 by IP/IPI E-test should be taken as positive for MBL activity. With the new dual interpretation criteria,
the MBL IP/IPI E-test was shown to achieve 100% sensitivity as well as specificity for the IRPA in this study. Therefore, the IP/IPI
E-test is a viable alternative phenotypic assay to detect MBL production in IRPA in our population in circumstances where PCR
detection is not a feasible option.
1. Introduction
Carbapenems, including imipenem (IPM or IP) and
meropenem, are themost potent antibacterial agents used for
the treatment of infections initiated by multidrug-resistant
gram-negative bacilli [1]. However, acquired resistance1
to carbapenems has been increasingly reported globally,
which can be attributed to the evolution of divergent β-
lactamases in numerous gram-negative bacteria (including
Pseudomonas aeruginosa). P. aeruginosa is an important
nosocomial pathogen that is intrinsically resistant tomultiple
antibiotics. Amongst the various β-lactamases that have
been identified to date, the genetically mobile metallo-β-
lactamases (MBLs) are the most versatile ones as they are
able to hydrolyse all β-lactams except monobactams [2].
Genes encoding for MBL were shown to be carried on large
transferable plasmids or were associated with transposons,
allowing horizontal transfer of these MBL genes among
diﬀerent bacterial genera and species [3]. To date, five
types of acquired MBL genes (IMP, VIM, SPM, GIM, and
SIM) have been identified based on their divergent protein
molecular structures [4–6]. While IMP and VIM variants
have been reported worldwide, members of SPM, GIM, and
SIM are restricted to certain geographical regions [7, 8].
Although PCR-based genotyping remains as the golden
standard for MBL detection and classification, its use
is mainly restricted to research purposes. As genotyping
information is necessary, diagnostic centers and laboratories
still rely mostly on culture-based phenotypic test as a means
for rapid detection of MBL activity. So far, many variations
of phenotypic assays for MBLs detection have been reported,
and these assays are not standardized. Early detection of
MBL-producing organisms is critical as it allows for the
prompt use of appropriate antibiotics to eﬀectively control
infection. It has been well documented that the activity of
MBLs is dependent on zinc or cadmium [4, 9–13]. Several
screening methods incorporating the use of metal chelating
agents, such as ethylenediaminetetraacetic acid (EDTA) and
thiol-based compounds like 2-mercaptopropionic acid (2-
MPA), which are capable of blocking MBL activity, have
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Figure 1: Phenotypic tests to detect MBL production. (a) Combined disk test (CDT) showing enhanced inhibition zone of >7mm around
IPM + EDTA disc indicating MBL positivity. (b) Double-disk synergy test (DDST) with synergistic zone of inhibition surrounding IPM and
2-mercaptopropionic acid (2-MPA) disks indicating MBL activity. (c) MBL IP/IPI E-test demonstrating enhanced MIC of imipenem in the
presence of EDTA IPI with IP/IPI of ≥8 for MBL activity.
been developed to detect MBL-producing organisms [14–
18]. A double-disk synergy test (DDST) using a IPM or
ceftazidime (CAZ) disk and a 2-MPA disk, designed by
Arakawa et al. [14], was able to indicate the presence
of MBLs through the display of an enhanced zone of
inhibition around the CAZ disk toward the 2-MPA disk.
In addition, a microdilution test [16] and a combined2
IPM-EDTA disk diﬀusion method [18] that both utilize
EDTA were also developed. The combined IPM-EDTA disk
test (CDT) works by comparing the zones of inhibition
obtained with IPM disks with and without EDTA [18]. In
contrast, the microdilution method compares the minimal
inhibitory concentrations (MIC) of IPM with and without
EDTA [16]. Both methods were reported to be reliable for
the detection of MBLs in carbapenem-resistant Pseudomonas
and Acinetobacter strains [16, 18]. Recently a commercial
E-test strip (AB BioDisk, Solna, Sweden), which oﬀers
antimicrobial resistance testing based on the reduction of
MICs of IPM in the presence of chelating agents (EDTA), was
also developed. The MBL imipenem/imipenem-inhibitor
(IP/IPI) E-test has been reported to be sensitive for the
detection of MBLs in Acinetobacter species, P. aeruginosa,
Serratia species, Stenotrophomonas maltophilia, and Bac-
teroides fragilis [17].
In our recent study we reported that prevalence of IPM-
resistant P. aeruginosa (IRPA) isolates in Malaysia is high;
both IMP and VIMMBLs, but not SIM, GIM, and SPM, were
detected in our local isolates [19]. Integron carrying blaVIM
and blaIMP genes in IRPA were found using a PCR-based
method [20]. In this study, three phenotypic methods (CDT,
DDST, and IP/IPI E-test) for MBL detection in IRPA clinical
isolates were evaluated in comparison to PCR detection of
MBL genes as the gold standard.
2. Materials andMethods
2.1. Clinical Isolates. A total of 90 IRPA isolated from various
clinical specimens of nonrepetitive patients admitted to the
University of Malaya Medical Centre (UMMC) were used for
this study [6]. These included (i) 5 isolates from Intensive
care unit (ICU) and 25 isolates from other wards, collected
from October 2005 to March 2006; (ii) 10 isolates from ICU
and 50 from other wards, collected from October 2007 to
March 2008. These isolates were identified as P. aeruginosa
by the Medical Microbiology Diagnostic Laboratory using
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Figure 2: Correlation analysis of combined disk test (CDT), MBL IP/IPI E-test, and PCR detection of MBL genes. (a) MBL index by CDT
was 9.5 and 13.4 for IRPA isolates that were negative and positive for MBL genes, respectively (P < 0.001). (b) MBL index by IP/IPI E-test
was 6.4 and 134.5 for IRPA isolates that were negative and positive for MBL genes, respectively (P < 0.001). Statistical analysis was carried
out using two-tailed Student’s t-test with P < 0.001 considered significant. (c) Strong correlation between IP MIC and MBL index with PCR
detection of MBL genes. Together, IP > 16 μg/mL andMBL index≥ 8 were able to distinguish IRPA withMBL genes from those without. The
proposed cutoﬀ values were determined from a receiver-operating characteristic (ROC) curve to obtain a 100% sensitivity and specificity for
this data set.
routine biochemical confirmatory tests. MBL gene detection
and genotyping was carried out as previously described [6].
2.2. Phenotypic Detection of MBL Activity
2.2.1. Combined Disk Test. The test was performed as
described by Yong et al. [18]. Briefly, an overnight culture
of an IRPA clinical isolate was diluted with peptone water
(Oxoid, USA) to 105 CFU/mL and spread onMueller-Hinton
(MH) agar (Difco, France) plate using cotton swab. Two
IPM disks (Oxoid, UK) were placed on the surface of
the agar at a distance of 4-5 cm from each other. 5 μL of
750 μg/mL EDTA solution (Gibco BRL, USA) was then added
to one of the IPM disks (Oxoid, UK). The inhibition zones
displayed around the IPM (Oxoid, UK) and the IPM-EDTA
disks were compared after 14 to 16 hrs of incubation at
37◦C (Figure 1(a)). The diﬀerence of ≥7mm between the
inhibition zone diameter of the IPM-EDTA disk and that of
IPMonly disk was considered to be a positive for the presence
of MBLs [18]. The procedure was repeated twice to ensure
the reproducibility of results.
2.2.2. Double Disk Synergy Test (DDST). DDST was per-
formed according to Lee et al. [13]. Briefly, an overnight
culture of an IRPA clinical isolate was diluted with peptone
water (Oxoid, USA) to 105 CFU/mL and spread on MH
agar (Difco, France) plate using cotton swab. Two IPM disks
(Oxoid, UK) were placed on the surface of the agar 4-5 cm
(center to center) apart. A blank filter disk (Oxoid, UK)
was subsequently placed near one of the IPM disks (Oxoid,
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UK) at a distance from 1.0 to 1.5 cm, and 3 μL of 2-MPA
(Sigma, USA) was applied onto the blank disk. The plate was
incubated overnight. The presence of a synergistic inhibitory
zone was regarded as MBL positive (Figure 1(b)).
2.2.3. MBL IP/IPI E-Test. An overnight culture of an IRPA
clinical isolate was diluted in peptone water to a turbidity
of a 0.5 McFarland standard. A cotton swab was then used
to transfer the inoculum onto a MH agar plate. Once
dried, an E-test MBL strip (AB BioDisk, Solna, Sweden) was
applied onto the plate which was then incubated at 37◦C
for 16 to 18 hrs to detect the presence of metalloenzymes.
Interpretation of results was carried out according to the
manufacturer’s instructions. A reduction in MIC in the
presence of EDTA of greater than or equal to eight-fold
(IP/IPI ≥ 8) is interpreted as indicating MBL activity
(Figure 1(c)).
2.3. Statistical Analysis. Statistical analysis was carried out
using two-tailed Student’s t-test with P < 0.001 considered
significant. Sensitivity was determined as number of true
positives/(number of true positives + number of false
negatives). Specificity was calculated as number of true
negatives/(number of true negatives + number of false
positives). Cutoﬀ values were determined using the SPSS
software (IBM, USA) graphically displayed as a receiver-
operating characteristic (ROC) curve.
3. Results and Discussion
Among 90 IRPA clinical isolates used in this study, MBL
genes (blaIMP-4, IMP-7, blaVIM-2,VIM-11) were detected in 32
isolates by PCR. In addition, these 32 isolates were also found
to be resistant to at least six antibiotics and, hence, regarded
as multidrug-resistant isolates.
In the evaluation of three selected MBL phenotypic
assays (CDT, DDST, and IP/IPI E-test) (Table 1), all three
methods were shown to have a sensitivity of 100%. However,
specificity of phenotypic assays diﬀers. DDST was the most
specific of the three (96.6%), followed by IP/IPI E-test with
the single criteria of IP/IPI ≥ 8 as positive (62.1%). CDT
was the least specific (43.1%). In all three phenotypic assays,
false-positive MBL producers were detected. These false-
positive cases might actually be producing an unknown and
weaker β-lactamases, which is worth further investigation.
Here, we demonstrated that DDST was more specific in
detecting MBLs in comparison to the CDT as also previously
described by Lee et al. [13] and Pitout et al. [12]. On the
other hand, this is unlike Qu et al. [21] who demonstrated
that the CDT is the best method for screening for MBL
production in P. aeruginosa from China. This discrepancy in
findings may be due to diﬀerences in population structure of
MBL genes between diﬀerent geographical areas (predom-
inantly VIM-2 and IMP-9 in China versus predominantly
VIM-2 and IMP-7 in Malaysia). Furthermore, there is no
significant diﬀerence observed in zone diameter increases for
VIM-2-producing P. aeruginosa compared to those for IMP-
7-producing isolates.
Unlike DDST, which is qualitative, CDT and IP/IPI E-
test are both semiquantitative in nature and enabled the
calculation of an MBL index. The MBL index of CDT and
IP/IPI E-test is an estimate of the relative level of MBL
activity and is comparable within the method. However,
since there are considerable diﬀerences in methodology
between CDT and IP/IPI E-test, theMBL indexes obtained by
these two methods are incomparable. The main advantage of
the IP/IPI E-test has been the only method among the three
studied that allows the MIC to be determined. Although
significant diﬀerences (P < 0.001) exist between the MBL
indexes of CDT (Figure 2(a)) and IP/IPI E-test (Figure 2(b))
as compared direct detection of MBL genes by PCR, distinct
subsets were obvious only with IP/IPI E-test between IRPA
with and without MBL genes (Figure 2(c)).
The high false-positive reporting rate attributed to CDT
is not surprising as the isolates tested in this study were
IPM resistant, and, therefore, the inhibition zone of ≥7mm
in zone diameter in the presence of EDTA may not be
considered as a definitive clear cutoﬀ criterion to diﬀerentiate
between MBL-producing and non-MBL-producing IPRA
isolates. In view of that, Yong et al. [18] reported that the best
separation between MBL-positive and MBL-negative isolates
was obtained using a breakpoint of ≥8mm in the presence
of 750 μg of EDTA instead. It is also important to note that
EDTA has membrane-permeabilising properties and could
exert a deleterious eﬀect on P. aeruginosa; thus, the extended
zone size diﬀerence between the IPM and IPM-EDTA disks
in the CDT may be due to the susceptibility of the organism
to EDTA rather than its metal-chelating eﬀect that inactivates
any MBL, thus resulting in false-positive detection [22].
In the present study, in accordance with our previous
PCR findings, the MBL IP/IPI E-test was demonstrated to
exhibit 100% accuracy in the detection of MBL production.
Our results were similar to the findings of Walsh et al. [17]
and also in another study on Acinetobacter baumannii by
Segal and Elisha [23]. Since true MBL-producing IRPA tends
to be more highly resistant to IPM (higher MIC) than non-
MBL-producing IRPA, our results suggest that those isolates
with IPMIC < 16 μg/mL be excluded from the determination
of MBL status by the IP/IPI E-test. In other words, we
suggest that only IPMIC > 16 μg/mL (proposed new criteria)
together with IP/IPI ≥ 8 (criteria by manufacturer) by E-test
should be taken as MBL activity-positive for IRPA isolated
fromMalaysian patients.With the new dual criteria, theMBL
IP/IPI E-test was able to achieve 100% sensitivity and 100%
specificity. A larger-scale study involving more IRPA strains
with larger geographical scope will be needed to verify the
validity of the new proposed criteria for interpreting theMBL
IP/IPI E-test.
Despite the accuracy of MBL IP/IPI E-test detection, it is
costly compared to the antibiotic disks to be used by health
care institutions or clinical laboratories for routine MBL
screening procedure. DDST, which exhibited up to 96.6%
specificity, is perhaps a more suitable routine screening
procedure to be considered for early detection of MBL-
producing bacteria. However, in order to minimize false pos-
itivity, isolates positive by DDST can be further confirmed by
MBL IP/IPI E-test.
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Table 1: Detection of MBL activity and MBL genes of IRPA clinical isolates from Malaysia.
Bacterial strain
CDT DDST IP/IPI E-test
PCR
IMP (mm) IMP + EDTA (mm) MBL index MBL index IP (μg/mL) IPI (μg/mL) MBL index
Ps1 10 22 12 + + 256 1 256 + IMP-7
Ps2 12 30 18 + + 256 4 64 + IMP-4
Ps3 10 24 14 + + 256 1 256 + IMP-4
Ps4 10 22 12 + + 192 <1 >192 + VIM-2
Ps5 10 20 10 + + 192 1 192 + VIM-2
Ps6 10 24 14 + + 192 <1 >192 + VIM-2
Ps7 10 25 15 + + 192 <1 >192 + VIM-2
Ps8 10 20 10 + + 192 <1 >192 + VIM-2
Ps9 11 21 10 + + 192 <1 >192 + VIM-2
Ps10 11 26 15 + + 192 1 192 + VIM-2
Ps11 10 24 14 + + 192 <1 >192 + VIM-2
Ps12 12 21 9 + + 192 2 96 + VIM-2
Ps13 12 22 10 + + 192 2 96 + VIM-2
Ps14 10 22 12 + + 192 <1 >192 + IMP-7
Ps15 12 30 18 + + 192 4 48 + IMP-7
Ps16 10 23 13 + + 192 2 96 + IMP-7
Ps17 10 23 13 + + 192 2 96 + IMP-7
Ps18 10 27 17 + + 192 2 96 + IMP-7
Ps19 10 17 7 + + 192 2 96 + IMP-7
Ps20 10 23 13 + + 128 2 64 + VIM-2
Ps21 10 25 15 + + 128 <1 >128 + VIM-2
Ps22 10 29 19 + + 128 <1 >128 + VIM-2
Ps23 10 27 17 + + 128 1 128 + VIM-11
Ps24 10 20 10 + + 128 <1 >128 + VIM-2
Ps25 10 33 23 + + 128 2 64 + VIM-2
Ps26 10 27 17 + + 128 2 64 + VIM-2
Ps27 11 21 10 + + 128 2 64 + VIM-2
Ps28 12 30 18 + + 128 1 128 + IMP-7
Ps29 12 21 9 + + 128 1 128 + IMP-7
Ps30 11 21 10 + + 128 1 128 + IMP-7
Ps31 10 23 13 + + 128 1 128 + IMP-7
Ps32 11 22 11 + + 96 <1 >96 + IMP-7
Ps33 10 22 12 + − 32 6 5 − −
Ps34 12 18 6 − − 24 4 6 − −
Ps35 10 27 17 + − 24 4 6 − −
Ps36 10 25 15 + − 24 4 6 − −
Ps37 12 23 11 + − 24 4 6 − −
Ps38 13 25 12 + − 24 4 6 − −
Ps39 10 19 9 + − 24 4 6 − −
Ps40 10 18 5 + − 24 4 6 − −
Ps41 10 25 15 + − 24 4 6 − −
Ps42 12 18 6 − − 24 4 6 − −
Ps43 10 20 10 + − 24 4 6 − −
Ps44 10 25 15 + + 24 4 6 − −
Ps45 9 30 21 + − 24 4 6 − −
Ps46 10 24 14 + − 24 4 6 − −
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Table 1: Continued.
Bacterial strain
CDT DDST IP/IPI E-test
PCR
IMP (mm) IMP + EDTA (mm) MBL index MBL index IP (μg/mL) IPI (μg/mL) MBL index
Ps47 10 16 6 − − 24 4 6 − −
Ps48 12 24 12 + − 24 4 6 − −
Ps49 13 20 7 + − 24 4 6 − −
Ps50 12 18 6 − − 16 2 8 + −
Ps51 10 20 10 + + 16 2 8 + −
Ps52 12 18 6 − − 16 3 5 − −
Ps53 11 21 10 + − 16 3 5 − −
Ps54 10 23 13 + − 16 3 5 − −
Ps55 13 25 12 + − 16 4 4 − −
Ps56 11 24 13 + − 16 3 5 − −
Ps57 11 21 10 + − 16 4 4 − −
Ps58 10 27 17 + − 16 4 4 − −
Ps59 12 23 11 + − 16 3 5 − −
Ps60 10 16 6 − − 16 3 5 − −
Ps61 10 22 12 + − 16 4 4 − −
Ps62 10 32 22 + − 16 3 5 − −
Ps63 10 22 12 + − 16 4 4 − −
Ps64 10 20 10 + − 16 4 4 − −
Ps65 11 21 10 + − 12 2 6 − −
Ps66 14 20 6 − − 12 2 6 − −
Ps67 13 18 5 − − 12 2 6 − −
Ps68 10 13 3 − − 12 3 4 − −
Ps69 12 14 2 − − 12 4 3 − −
Ps70 10 27 17 + − 12 2 6 − −
Ps71 10 20 10 + − 8 <1 >8 + −
Ps72 12 21 9 + − 8 <1 >8 + −
Ps73 12 21 9 + − 8 <1 >8 + −
Ps74 10 24 14 + − 8 <1 >8 + −
Ps75 10 14 4 − − 8 <1 >8 + −
Ps76 12 30 18 + − 8 <1 >8 + −
Ps77 12 18 6 − − 8 <1 >8 + −
Ps78 12 18 6 − − 8 <1 >8 + −
Ps79 10 16 6 − − 8 1 8 + −
Ps80 11 17 6 − − 8 1 8 + −
Ps81 12 18 6 − − 8 <1 >8 + −
Ps82 12 18 6 − − 8 <1 >8 + −
Ps83 14 18 4 − − 8 <1 >8 + −
Ps84 13 17 4 − − 8 <1 >8 + −
Ps85 13 19 6 − − 8 <1 >8 + −
Ps86 12 18 6 − − 8 1 8 + −
Ps87 12 18 6 − − 8 1 8 + −
Ps88 10 14 4 − − 8 <1 >8 + −
Ps89 11 15 4 − − 8 <1 >8 + −
Ps90 12 17 5 − − 8 <1 >8 + −
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In conclusion, MBL detection remains a controversial
issue, and clinical laboratories are in need of a simple and
direct method to recognize such resistance in gram-negative
bacteria to improve disease management. Furthermore, in
recognition that MBL genotypes are not homogenous in
geographical distribution, a generalized criteria for inter-
pretation of MBL phenotypic assays may not be possible.
Thus, it is recommended that the phenotypic assays should
be assessed and adopted based on the local situation.
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